The “Pharmaceutical Clinical Contract Peripheral Services, 2025-2030” report has been added to ResearchAndMarkets.com’s offering.

Global CRO industry was valued at $66.39 billion in 2024, and it is expected to register a CAGR of 10.7% from 2024 to 2030, reaching $122.13 billion in 2030. Across the global pharma market, the overall CRO outsourcing penetration rate ranges from 45%-50%, depending on the service type.

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial turnarounds and improved time to market.

In addition to full-service CROs operating in the global CRO industry, there is a surge of peripheral service-focused CROs, also referred to as specialized/niche CROs. These companies exclusively focus on supportive functions, including biostatistics, lab testing, pharmacovigilance, post-market surveillance, and investigational product (IP) management. These activities support the core clinical research functions, ensuring timely completion and required outcomes.

As the emphasis on biologics drug development grows, small-to-mid-sized and emerging biopharma companies are contributing more than 50% of the pipelines. Apart from trial-related services, such as patient recruitment, site selection and management, and investigator recruitment, clinical trial peripheral services, such as pharmacovigilance, safety testing, central lab services, medical writing, IP management, data management, and biostatistics, have been gaining traction, with pharma sponsors increasingly outsourcing these specific activities to CROs.

This is leading to the extensive use of the functional service provider (FSP) model targeting specific trial-related ancillary or peripheral activities. Though a significant share of the clinical pipeline is contributed by small-to-mid-sized and emerging biopharma companies, the need for peripheral services through FSP models is expected to witness a sharp rise, especially from large pharma companies looking to optimize trial costs.

Moreover, the industry will witness a shift to a hybrid FSO/FSP model, as companies aim to augment their clinical trial activities through better risk mitigation. As a result, these companies will look for outsourcing partners to meet their clinical research needs, paving the way for both full-service outsourcing and FSP models, which focus on supporting peripheral activities, such as analytical testing, data management, and biostatistics.

Key Issues Addressed

• What are the general industry trends? What are the specific trends for peripheral activities within clinical trials?
• What are the key drivers triggering large-scale outsourcing of clinical development?
• What key emerging business models are providing a competitive advantage to pharma sponsors? How is this trend supporting industry convergence?
• Who are the leading participants driving market growth?
• What is the growth opportunity for small-to-mid-sized CRO companies amidst 1,500+ competitors?
• How is the application of technology supporting the growth of the CRO peripheral activities landscape? Which are the fastest-growing peripheral activities in the CRO industry?

Growth Opportunities

• Medical Co-pilot-powered Clinical Trial Data Management
• Central Lab Services for Biotechnology Companies in Australia
• Customized Services for Regulatory and Medical Affairs
• Pharmacovigilance-as-a-Service
• Customer-centric Partnership Models for Peripheral Service Outsourcing

Key Topics Covered:

Growth Opportunities: Research Scope

• Scope of Analysis
• Segmentation
• CRO Peripheral Services – Defining Key Activities Across Peripheral Services

Growth Environment: Transformation in the Pharmaceutical Clinical Contract Peripheral Services Landscape

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative
• The Impact of the Top 3 Strategic Imperatives on the Pharmaceutical Clinical Contract Peripheral Services Industry

Ecosystem in the Pharmaceutical Clinical Contract Research Organization Industry

• Market Trend Analysis
• Contract Peripheral Services – Vendor Ecosystem
• CRDMO – The New Normal in Early-stage Drug Development
• Evolving Partnership Models Across the CRO Market
• FSP Model Types
• FSP Model Outlook

Competitive Environment

• Key Competitors – By Regions

Best Practices in the Pharmaceutical Clinical Contract Research Organization Industry

• Investment Trends
• Portfolio Expansion with M&As
• Project-specific CRO Expertise With Strategic Partnerships
• In-house Investments for Long-term Growth

Growth Generator in the Pharmaceutical Clinical Contract Research Organization Industry

• Growth Metrics
• Growth Drivers
• Growth Restraints
• Forecast Assumptions
• Market Forecast – Limitations and Caveats
• Revenue Forecast Methodology
• Revenue Forecast
• Revenue Forecast Analysis

Revenue Forecast by Clinical Development Phase

• Percent Revenue Share by Clinical Development Phase
• Revenue Forecast Analysis by Clinical Development Phase
• Revenue Share
• Revenue Share Analysis
• Revenue Forecast by Region
• Percent Revenue Forecast by Region
• Revenue Forecast by Peripheral Services Versus Core Services
• Percent Revenue Forecast by Peripheral Services Versus Core Services
• Revenue Forecast by Peripheral Service Segments
• Revenue Forecast Analysis

Growth Generator in the Pharmaceutical Clinical Contract Research Organization Industry

• Central Lab Testing Services
• Central Lab Testing Services – Revenue Forecast
• Central Lab Testing Services – Revenue Forecast by Region
• Central Lab Testing Services – Revenue Forecast Discussion

Growth Generator in the Pharmaceutical Clinical Contract Research Organization Industry

Growth Generator in the Pharmaceutical Clinical Contract Research Organization Industry

Growth Generator in the Pharmaceutical Clinical Contract Research Organization Industry

Growth Generator in the Pharmaceutical Clinical Contract Research Organization Industry

Growth Generator in the Pharmaceutical Clinical Contract Research Organization Industry

Growth Generator in the Pharmaceutical Clinical Contract Research Organization Industry

Appendix & Next Steps

For more information about this report visit here.